AR061815A1 - Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento - Google Patents
Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamentoInfo
- Publication number
- AR061815A1 AR061815A1 ARP070102985A ARP070102985A AR061815A1 AR 061815 A1 AR061815 A1 AR 061815A1 AR P070102985 A ARP070102985 A AR P070102985A AR P070102985 A ARP070102985 A AR P070102985A AR 061815 A1 AR061815 A1 AR 061815A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkynyl
- alkenyl
- alkyl
- optionally substituted
- halogen
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- HWHWCOBKVKZESC-BYPYZUCNSA-N (2s)-3-oxopyrrolidine-2-carboxamide Chemical compound NC(=O)[C@H]1NCCC1=O HWHWCOBKVKZESC-BYPYZUCNSA-N 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 102100037602 P2X purinoceptor 7 Human genes 0.000 abstract 2
- 101710189965 P2X purinoceptor 7 Proteins 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000005002 aryl methyl group Chemical group 0.000 abstract 2
- 125000004981 cycloalkylmethyl group Chemical group 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- -1 Oxo-prolinamide compound Chemical class 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0613473A GB0613473D0 (en) | 2006-07-06 | 2006-07-06 | Novel compounds |
| GB0622825A GB0622825D0 (en) | 2006-11-15 | 2006-11-15 | Novel compounds |
| GB0705263A GB0705263D0 (en) | 2007-03-19 | 2007-03-19 | Novel compounds |
| GB0711439A GB0711439D0 (en) | 2007-06-13 | 2007-06-13 | Novel receptor antagonists and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061815A1 true AR061815A1 (es) | 2008-09-24 |
Family
ID=38508907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102985A AR061815A1 (es) | 2006-07-06 | 2007-07-04 | Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7718693B2 (enExample) |
| EP (1) | EP2049478B1 (enExample) |
| JP (1) | JP5283620B2 (enExample) |
| KR (2) | KR101398264B1 (enExample) |
| AR (1) | AR061815A1 (enExample) |
| AU (1) | AU2007271182B2 (enExample) |
| BR (1) | BRPI0714062A2 (enExample) |
| CA (1) | CA2655675A1 (enExample) |
| CR (2) | CR10545A (enExample) |
| CY (1) | CY1113415T1 (enExample) |
| DK (1) | DK2049478T3 (enExample) |
| EA (1) | EA016076B1 (enExample) |
| ES (1) | ES2385505T3 (enExample) |
| HR (1) | HRP20120505T1 (enExample) |
| IL (1) | IL196181A0 (enExample) |
| MA (1) | MA30607B1 (enExample) |
| MX (1) | MX2009000117A (enExample) |
| NO (1) | NO20090267L (enExample) |
| PE (1) | PE20080997A1 (enExample) |
| PL (1) | PL2049478T3 (enExample) |
| PT (1) | PT2049478E (enExample) |
| SI (1) | SI2049478T1 (enExample) |
| TW (1) | TW200819127A (enExample) |
| UA (1) | UA100227C2 (enExample) |
| WO (1) | WO2008003697A1 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602007011628D1 (de) | 2006-07-06 | 2011-02-10 | Array Biopharma Inc | Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren |
| RU2481336C2 (ru) | 2006-07-06 | 2013-05-10 | Эррэй Биофарма Инк. | Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт |
| AU2007271182B2 (en) | 2006-07-06 | 2012-03-15 | Glaxo Group Limited | Substituted N-phenylmethyl -5-oxo-proline-2-amides as P2X7-receptor antagonists and their methods of use |
| US8063050B2 (en) * | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| WO2008006039A1 (en) | 2006-07-06 | 2008-01-10 | Array Biopharma Inc. | Dihydrothieno pyrimidines as akt protein kinase inhibitors |
| DE102006047617B4 (de) * | 2006-10-09 | 2008-11-27 | Clariant International Limited | Verfahren zur Herstellung basischer (Meth)acrylamide |
| DE102006047619B4 (de) * | 2006-10-09 | 2008-11-13 | Clariant International Limited | Verfahren zur Herstellung basischer Fettsäureamide |
| MX2009004291A (es) * | 2006-10-22 | 2009-09-07 | Idev Technologies Inc | Metodos para asegurar extremos de hebra y los dispositivos resultantes. |
| GB0705882D0 (en) | 2007-03-27 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
| EP2139858A1 (en) * | 2007-03-28 | 2010-01-06 | Glaxo Group Limited | Piperidinone carboxamide derivatives as p2x7 modulators |
| EP2139875A2 (en) * | 2007-03-29 | 2010-01-06 | Glaxo Group Limited | Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators |
| EA200970912A1 (ru) | 2007-04-03 | 2010-02-26 | Глэксо Груп Лимитед | Карбоксамидные производные имидазолидина в качестве модуляторов p2x7 |
| MX2009014013A (es) | 2007-07-05 | 2010-01-28 | Array Biopharma Inc | Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt. |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| CA2692502C (en) | 2007-07-05 | 2016-03-01 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| WO2009074518A1 (en) * | 2007-12-12 | 2009-06-18 | Glaxo Group Limited | Combinations of prolinamide p2x7 modulators with further therapeutic agents |
| GB0724625D0 (en) * | 2007-12-18 | 2008-01-30 | Glaxo Group Ltd | Novel compounds |
| US20100292295A1 (en) * | 2007-12-18 | 2010-11-18 | Glaxo Group Limited | 5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators |
| US8853216B2 (en) | 2008-01-09 | 2014-10-07 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor |
| US8835434B2 (en) | 2008-01-09 | 2014-09-16 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| GB0803729D0 (en) * | 2008-02-29 | 2008-04-09 | Ge Healthcare Ltd | Imaging the central nervous system |
| AU2009228649B2 (en) | 2008-03-25 | 2014-05-22 | Affectis Pharmaceuticals Ag | Novel P2X7R antagonists and their use |
| DE102008017218B4 (de) * | 2008-04-04 | 2011-09-22 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Amiden niederer aliphatischer Carbonsäuren |
| DE102008017213B4 (de) * | 2008-04-04 | 2012-08-09 | Clariant International Limited | Kontinuierliches Verfahren zur Herstellung von Amiden aliphatischer Hydroxycarbonsäuren |
| DE102008017214B4 (de) * | 2008-04-04 | 2012-02-16 | Clariant International Limited | Kontinuierliches Verfahren zur Herstellung von Fettsäurealkanolamiden |
| DE102008017217A1 (de) * | 2008-04-04 | 2009-10-08 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Amiden aromatischer Carbonsäuren |
| DE102008017215B4 (de) * | 2008-04-04 | 2012-08-09 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Amiden ethylenisch ungesättigter Carbonsäuren |
| DE102008017216B4 (de) * | 2008-04-04 | 2013-08-14 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden |
| DE102008017219A1 (de) * | 2008-04-04 | 2009-10-08 | Clariant International Ltd. | Verfahren zur Herstellung von Amiden in Gegenwart von überhitztem Wasser |
| US8629157B2 (en) | 2009-01-05 | 2014-01-14 | Boehringer Ingelheim International Gmbh | Pyrrolidine compounds which modulate the CB2 receptor |
| DK2243772T3 (da) | 2009-04-14 | 2012-02-13 | Affectis Pharmaceuticals Ag | Hidtil ukendte P2X7R-antagonister og deres anvendelse |
| DE102009031059A1 (de) | 2009-06-30 | 2011-01-05 | Clariant International Ltd. | Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen |
| DE102009042523B4 (de) | 2009-09-22 | 2012-02-16 | Clariant International Ltd. | Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen |
| DE102009042522A1 (de) | 2009-09-22 | 2011-04-07 | Clariant International Ltd. | Kontinuierliches Umesterungsverfahren |
| DK2509609T3 (da) * | 2009-12-08 | 2014-11-10 | Univ Vanderbilt | Forbedrede fremgangsmåder og sammensætninger for venehøst og autotransplantation |
| WO2011109833A2 (en) | 2010-03-05 | 2011-09-09 | President And Fellows Of Harvard College | Induced dendritic cell compositions and uses thereof |
| EP2386541A1 (en) | 2010-05-14 | 2011-11-16 | Affectis Pharmaceuticals AG | Novel methods for the preparation of P2X7R antagonists |
| DE102010056564A1 (de) | 2010-12-30 | 2012-07-05 | Clariant International Limited | Hydroxylgruppen und Estergruppen tragende Polymere und Verfahren zu ihrer Herstellung |
| DE102010056565A1 (de) | 2010-12-30 | 2012-07-05 | Clariant International Ltd. | Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere |
| CN103402996B (zh) * | 2011-01-04 | 2015-02-11 | 诺瓦提斯公司 | 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物 |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| CA2828456C (en) * | 2011-03-03 | 2021-05-04 | Zalicus Pharmaceuticals Ltd. | N-benzl-amino-carboxamide inhibitors of the sodium channel |
| TR201815685T4 (tr) | 2011-04-01 | 2018-11-21 | Genentech Inc | Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları. |
| FI2694072T4 (fi) | 2011-04-01 | 2024-09-30 | Genentech Inc | Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| MX2014000894A (es) | 2011-07-22 | 2014-02-27 | Actelion Pharmaceuticals Ltd | Derivados de amidas heterociclicas como antagonistas de receptores p2x7. |
| TWI576347B (zh) | 2012-01-20 | 2017-04-01 | 艾克泰聯製藥有限公司 | 作為ｐ２ｘ受體拮抗劑之雜環醯胺衍生物 |
| US9075975B2 (en) * | 2012-02-21 | 2015-07-07 | Andrew Bud | Online pseudonym verification and identity validation |
| KR102232742B1 (ko) | 2012-12-12 | 2021-03-26 | 이도르시아 파마슈티컬스 리미티드 | Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체 |
| WO2014097140A1 (en) | 2012-12-18 | 2014-06-26 | Actelion Pharmaceuticals Ltd | Indole carboxamide derivatives as p2x7 receptor antagonists |
| JP6282016B2 (ja) | 2013-01-22 | 2018-02-21 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体 |
| JP6282017B2 (ja) | 2013-01-22 | 2018-02-21 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体 |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| FR3026102A1 (fr) * | 2014-09-19 | 2016-03-25 | Univ Nice Sophia Antipolis | Conjugues d'acide amine-pyridine/pyridinium et leurs utilisations en tant qu'agents biocides |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| ME03794B (me) | 2016-05-31 | 2021-04-20 | Kalvista Pharmaceuticals Ltd | Derivati pirazola kao inhibitori kalikreina plazme |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| DE102016111711A1 (de) * | 2016-06-27 | 2017-12-28 | Abb Schweiz Ag | Installationsschaltgerät mit einem Gehäuse und mit einer Schraubanschlussklemme |
| AU2018235561B2 (en) * | 2017-03-13 | 2020-06-18 | Asahi Kasei Pharma Corporation | Tetrahydroquinoline derivatives as P2X7 receptor antagonists |
| US20200123104A1 (en) * | 2017-06-28 | 2020-04-23 | Indiana University Research And Technology Corporation | Pharmaceutical agent that binds the p2x7 receptor |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| PL3716952T3 (pl) | 2017-11-29 | 2022-05-02 | Kalvista Pharmaceuticals Limited | Postacie dawkowania zawierające inhibitor kalikreiny osoczowej |
| EP3773557A1 (en) | 2018-03-29 | 2021-02-17 | Centre national de la recherche scientifique | P2rx7 modulators in therapy |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| WO2021201680A1 (en) | 2020-03-31 | 2021-10-07 | Hasan Djohan | Treatment of hyperinflammatory syndrome |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2651639A (en) | 1951-08-22 | 1953-09-08 | American Cyanamid Co | 2-pyrrolidone-5-carboxamide derivatives and methods of preparing the same |
| FR2273533A1 (fr) * | 1974-06-04 | 1976-01-02 | Ferlux Sa | Nouveaux derives n-substitues d'acides pyrrolidones-2 carboxyliques-5 |
| JPH0699307B2 (ja) | 1987-08-20 | 1994-12-07 | キッセイ薬品工業株式会社 | 抗痴呆剤 |
| US4772601A (en) | 1988-01-25 | 1988-09-20 | Hoechst-Roussel Pharmaceuticals, Inc. | 5-Substituted 1-(4-(1-pyrrolidinyl)-2-butynyl)-2-pyrrolidinones, pharmaceutical compositions and use |
| US6191146B1 (en) | 1995-11-13 | 2001-02-20 | Smithkline Beecham Corporation | Hemoregulatory compounds |
| US6054579A (en) | 1997-06-26 | 2000-04-25 | Leukosite, Inc. | Synthesis of substituted lactams |
| SE9704546D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704544D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| CA2355296A1 (en) * | 1998-12-11 | 2000-06-15 | American Biogenetic Sciences, Inc. | Substituted nitrogen heterocyclic compounds and therapeutic uses thereof |
| CN1215028C (zh) | 2002-05-24 | 2005-08-17 | 中国科学院上海有机化学研究所 | 外消旋的联二酚的光学拆分方法 |
| US7288538B2 (en) * | 2003-02-20 | 2007-10-30 | Encysive Pharmaceuticals, Inc. | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists |
| AU2004273610B2 (en) * | 2003-09-22 | 2010-07-01 | Onepharm Research & Development Gmbh | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss |
| US20080021034A1 (en) * | 2006-04-10 | 2008-01-24 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
| US20080076924A1 (en) * | 2006-06-30 | 2008-03-27 | Patrick Betschmann | Piperazines as P2X7 antagonists |
| AU2007271182B2 (en) * | 2006-07-06 | 2012-03-15 | Glaxo Group Limited | Substituted N-phenylmethyl -5-oxo-proline-2-amides as P2X7-receptor antagonists and their methods of use |
| ES2391671T3 (es) * | 2006-07-22 | 2012-11-28 | Oxagen Limited | Compuestos con actividad antagonista de CRTH2 |
| CA2670636A1 (en) * | 2006-11-27 | 2008-06-05 | H. Lundbeck A/S | Heteroaryl amide derivatives |
| US8093265B2 (en) * | 2007-03-09 | 2012-01-10 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| GB0705882D0 (en) * | 2007-03-27 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
| EP2139858A1 (en) * | 2007-03-28 | 2010-01-06 | Glaxo Group Limited | Piperidinone carboxamide derivatives as p2x7 modulators |
| EP2139875A2 (en) * | 2007-03-29 | 2010-01-06 | Glaxo Group Limited | Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators |
| EA200970912A1 (ru) * | 2007-04-03 | 2010-02-26 | Глэксо Груп Лимитед | Карбоксамидные производные имидазолидина в качестве модуляторов p2x7 |
| CN103204852A (zh) * | 2007-04-10 | 2013-07-17 | H.隆德贝克有限公司 | 作为p2x7拮抗剂的杂芳基酰胺类似物 |
-
2007
- 2007-07-03 AU AU2007271182A patent/AU2007271182B2/en not_active Ceased
- 2007-07-03 EP EP07787001A patent/EP2049478B1/en not_active Not-in-force
- 2007-07-03 SI SI200730962T patent/SI2049478T1/sl unknown
- 2007-07-03 BR BRPI0714062-2A patent/BRPI0714062A2/pt not_active IP Right Cessation
- 2007-07-03 KR KR1020097002352A patent/KR101398264B1/ko not_active Expired - Fee Related
- 2007-07-03 PL PL07787001T patent/PL2049478T3/pl unknown
- 2007-07-03 KR KR1020147001116A patent/KR20140016431A/ko not_active Ceased
- 2007-07-03 US US11/772,977 patent/US7718693B2/en not_active Expired - Fee Related
- 2007-07-03 CA CA002655675A patent/CA2655675A1/en not_active Abandoned
- 2007-07-03 MX MX2009000117A patent/MX2009000117A/es active IP Right Grant
- 2007-07-03 ES ES07787001T patent/ES2385505T3/es active Active
- 2007-07-03 UA UAA200900103A patent/UA100227C2/uk unknown
- 2007-07-03 DK DK07787001.2T patent/DK2049478T3/da active
- 2007-07-03 HR HRP20120505TT patent/HRP20120505T1/hr unknown
- 2007-07-03 PT PT07787001T patent/PT2049478E/pt unknown
- 2007-07-03 WO PCT/EP2007/056675 patent/WO2008003697A1/en not_active Ceased
- 2007-07-03 JP JP2009517252A patent/JP5283620B2/ja not_active Expired - Fee Related
- 2007-07-03 EA EA200970085A patent/EA016076B1/ru not_active IP Right Cessation
- 2007-07-04 AR ARP070102985A patent/AR061815A1/es unknown
- 2007-07-04 PE PE2007000855A patent/PE20080997A1/es not_active Application Discontinuation
- 2007-07-04 TW TW096124227A patent/TW200819127A/zh unknown
-
2008
- 2008-12-19 CR CR10545A patent/CR10545A/es unknown
- 2008-12-25 IL IL196181A patent/IL196181A0/en unknown
-
2009
- 2009-01-16 NO NO20090267A patent/NO20090267L/no not_active Application Discontinuation
- 2009-01-30 MA MA31599A patent/MA30607B1/fr unknown
-
2010
- 2010-02-18 US US12/708,077 patent/US8048907B2/en not_active Expired - Fee Related
-
2012
- 2012-07-26 CY CY20121100671T patent/CY1113415T1/el unknown
-
2014
- 2014-11-10 CR CR20140515A patent/CR20140515A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| AR066583A1 (es) | Derivados de 3,3-espiroindolinona | |
| CY1118292T1 (el) | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| UY28026A1 (es) | 4-piperazinilbencenosulfonilindoles y usos de los mismos. | |
| CL2008002863A1 (es) | Compuestos derivados de 1,1,1-trifluoro-2-hidroxi-3-fenilpropano sustituidos; el procedimiento de preparacion de los compuestos; su composicion farmaceutica; y uso en el tratamiento de la diabetes y enfermedades mediadas por glucocorticoides. | |
| AR076171A1 (es) | Pirazolopirimidinonas 1,6-disustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del alzheimer, epilepsia y otras enfermedades del sistema nervioso central. | |
| PA8783601A1 (es) | Derivados de piperidina/piperazina | |
| ECSP077185A (es) | Derivados de piridina | |
| AR070636A1 (es) | Derivados de piridina, composicion farmaceutica y uso terapeutico | |
| AR083610A1 (es) | COMPUESTOS TRICICLICOS COMO INHIBIDORES DE PROSTAGLANDINA E SINTASA-1 MICROSOMICA (mPGES-1) | |
| AR049126A1 (es) | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. | |
| AR073314A1 (es) | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol | |
| UY30316A1 (es) | Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| AR072809A1 (es) | Compuesto de (3- piridinilcarbonil)-4-(fenilsulfonilpiperazina ), su uso para la elaboracion de unmedicamento para el tratamiento del dolor y composicion farmaceutica que lo comprende | |
| UY29427A1 (es) | Derivados sustituidos de 2,3,4,5- tetrahidro-1h-pirido (4,3-b) indol, composiciones que los contienen, procesos de preparación y aplicaciones | |
| HRP20080052T3 (hr) | Derivati tropana supstituirani imidazopiridinom santagonističkim djelovanjem na ccr5 receptor za liječenje hiv-a i upala | |
| CY1116190T1 (el) | Φαρμακευτικη συνθεση η οποια περιεχει οπτικα ενεργη ενωση που διαθετει δραστικοτητα αγωνιστη υποδοχεα θρομβοποιητινης και ενδιαμεσο γι' αυτην | |
| AR034249A1 (es) | Uso de derivados de quinolina como antagonistas alfa-2; compuestos derivados de quinolina y sus composiciones | |
| ECSP099442A (es) | Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona | |
| AR072189A1 (es) | Derivados heterociclicos de benzo[b][1,4] oxazinonas moduladores de adrenoreceptores beta 2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de enfermedades del aparato respiratorio. | |
| AR045155A1 (es) | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
| AR049711A1 (es) | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso | |
| ATE530182T1 (de) | Pharmazeutische zubereitungen enthaltend nk1- rezeptoren antagonisten und natriumkanal blockierende verbindungen | |
| DOP2022000015A (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos |